Shanghai Haohai Biological Technology Co., Ltd. provided earnings guidance for the six-months ended 30 June 2020. For the period, the company expects that the Group would record an unaudited net profit attributable to the shareholders of the company of approximately RMB 27.5272 million during the Reporting Period (corresponding period in 2019: approximately RMB 182.5680 million), representing a decrease of approximately 85% as compared to the corresponding period in 2019; the unaudited net profit attributable to the shareholders of the Company after deducting the non-recurring profit and loss is expected to be approximately RMB 7.8299 million (corresponding period in 2019: unaudited net profit attributable to the shareholders of the Company after deducting the non-recurring profit and loss was approximately RMB 183.8932 million), representing a decrease of approximately 96% as compared to the corresponding period in 2019.